Gemcitabine–oxaliplatin (GEMOX) for epithelial ovarian cancer patients resistant to platinum-based chemotherapy
Conclusion The GEMOX combination is a regimen with a moderate therapeutic efficacy and tolerable toxic side effects in patients with platinum-resistant EOC.
Source: Journal of the Egyptian National Cancer Institute - Category: Cancer & Oncology Source Type: research
More News: Anemia | Cancer | Cancer & Oncology | Chemotherapy | Eloxatin | Epithelial Cancer | Hematology | Ovarian Cancer | Ovaries | Toxicology